Alzheimer's drugs market to be valued at $16.43b by 2033

Technologies like genomics, neuroimaging, and biomarker analysis drive growth.

The Alzheimer’s drugs market is expected to reach $16.43b by 2033 at a compound annual growth rate of approximately 9%, said Research and Markets.

The sector’s expansion is attributed to the rising prevalence of Alzheimer's disease, developments in medication development, and increasing governmental and private financing for neurological disease research.

“To expedite market access, regulatory bodies are simplifying the approval procedures for medications used to treat Alzheimer's disease,” the report said.

Meanwhile, technologies such as genomics, neuroimaging, and biomarker analysis make clinical trials and drug efficacy evaluations easier, contributing to market growth.